Exact Sciences Seeks Director of Medical Development to Lead MRD Breast Cancer Portfolio Strategy
核心洞察
Exact Sciences (搜索) is recruiting a Director of Medical Development to lead clinical and translational strategy for its molecular residual disease (MRD) liquid biopsy portfolio in breast cancer (搜索).
The role involves designing NGS-based assays, overseeing clinical validation studies, and guiding regulatory approval for diagnostic tests aimed at detecting residual disease and monitoring therapy effectiveness.
The position requires an M.D. with fellowship training in medical oncology, demonstrated molecular oncology expertise, and experience leading cross-functional teams.
Exact Sciences (搜索), a leader in cancer diagnostics, is expanding its precision oncology capabilities with a newly posted Director of Medical Development position focused on the molecular residual disease (MRD) breast portfolio. The role signals the company's deepening investment in liquid biopsy technology for breast cancer (搜索) management, spanning detection of residual disease, therapy monitoring, and treatment selection.
The Director will provide clinical and translational leadership in developing and executing the company's precision oncology strategies, including the design and implementation of next-generation sequencing (NGS)-based assays. These diagnostic tests are intended to help determine the most appropriate therapies for breast cancer (搜索) patients, monitor therapy effectiveness, and detect the presence of residual disease following treatment.
Strategic Scope and Responsibilities
The position carries broad responsibility across the product lifecycle. In partnership with Product and Medical Strategy teams, the Director will provide medical leadership during the design, implementation, and reporting of studies supporting pipeline products and line extensions to on-market products. The role encompasses the Oncotype DX (搜索) recurrence score, the OncoExTra (搜索) therapy selection portfolio, the MRD liquid biopsy portfolio, and digital pathology algorithms as they apply to breast cancer (搜索) clinical care.
A key function involves cultivating external relationships with oncology leaders at academic institutions, cooperative groups, and research organizations. The Director will initiate and lead external advisory boards involving medical leaders in pharma, key opinion leaders, and other third parties. Additionally, the role is accountable for scientific presentations and publications generated from product development collaborations.
Cross-Functional Leadership
The Director will serve as both a leader of and participant on internal cross-functional program teams, collaborating with business development, research and development, pathology and clinical lab operations, biostatistics, clinical affairs, medical affairs, regulatory, market access, and commercial teams. The position also includes serving as the medical monitor on study teams and leading the development and implementation of clinical protocols required to support product development, validation, and commercialization.
Qualifications and Compensation
Minimum qualifications include an M.D. or D.O. degree with completion of fellowship training in medical oncology, demonstrated expertise in molecular oncology, and proven ability to lead cross-functional teams on complex, multi-faceted projects. Preferred qualifications include two or more years of healthcare experience, oncology experience within the pharmaceutical or biotech industry with an emphasis on clinical or translational research, and strong knowledge of FDA and ex-U.S. regulatory documentation and processes.
The position offers a salary range of $300,000 to $344,000 annually, with bonus eligibility. The role can be based in Redwood City, CA, San Diego, CA, or be field-based, with travel expected up to 30% of working time.
Exact Sciences (搜索) continues to build its precision oncology portfolio as the company works to change how cancer is prevented, detected, and treated, giving patients and clinicians the clarity needed to make confident decisions.